^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NC410
i
Other names: NC410
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
NextCure
Drug class:
Cytotoxic T lymphocyte stimulant, Dendritic cell activator, LAIR1 antagonist
Related drugs:
4ms
KEYNOTE-D88: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=209, Recruiting, NextCure, Inc. | N=131 --> 209
Enrollment change • Checkpoint inhibition • Metastases
|
MSI (Microsatellite instability)
|
Keytruda (pembrolizumab) • NC410
9ms
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=131, Recruiting, NextCure, Inc. | Phase classification: P1b/2 --> P1/2
Phase classification
|
MSI (Microsatellite instability)
|
Keytruda (pembrolizumab) • NC410
10ms
Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice. (PubMed, Cancer Immunol Immunother)
However, combined targeting of LAIR-1 and PD-L1 results in increased tumour control. Thus, additional targeting of the LAIR-1:collagen pathway with NC410 is a promising approach to treating tumours where conventional immunotherapy is ineffective.
Preclinical • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
|
LAIR1 expression
|
NC410
Share via
